contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


orion-corporation-transfer-of-191911-own-b-shares-on-10-march-2025

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Orion operates in the pharmaceutical industry. The company conducts research and development of human and veterinary drugs, where the main focus is on diseases that affect the nervous system, as well as oncology and respiratory diseases. Today, the company's products are found on a global level, with the largest presence in the Nordic region and the rest of Europe. The company's head office is located in Espoo, Finland.

Orion Nubeqa, competitors and patent protection

From Orion’s own presentations, I have gotten the impression that the dividend will be increased only very moderately for two reasons. Firstly, it ensures a steady increase in the long term. The second reason is, in my opinion, more significant for shareholders: this way, more firepower is obtained for launching future blockbuster drugs entirely on their own, in which case the returns are of a different magnitude than when done through partners. This would enable a positive self-reinforcing development that could elevate Orion to a completely new size category. The prerequisite, of course, is that these blockbuster drugs can be created. So, the dividend will not be over two euros but closer to the current level, but that is a good thing for us shareholders.

It’s quite quiet on the Orion board. The €180M milestone payment didn’t change forecasts, as it was likely already factored in by everyone. The share price is also stagnant, even though the average target price, when the lowest (€46) and highest (€79) forecasts are excluded, is still €72.25. Quite a bit above today’s price. No more milestone payments are coming from Bayer, but next year’s growing royalties may well compensate for it. Nubeqa revenues for next year are unlikely to decrease much, if at all. Tenax Therapeutics’ share price in the US is on a fairly strong rise, +66% in the last month. That is the small outfit (with a market value only a third of Fermion’s) that is bringing Orion-licensed Levosimendan to market, now in oral form, for somewhat new indications. This is practically their only project, so it’s interesting for Orion shareholders as well. Phase 3 is progressing according to plan for FDA approval, and a global Phase 3 supplemental study is also underway. Funding for these is in order. Orion is set to receive 10 MUSD for FDA approval and a total of 60 MUSD in milestone payments. The patent for Levosimendan has already expired, so royalties are low (around 10%), but overall the drug is expected to have a market nearly as large as Nubeqa’s, so annual revenues of a couple of hundred million euros could well be reached in time. At least some in the New York Stock Exchange seem to believe in this company. MSD’s Phase 3 trials are also progressing. These involve a total of 1,730 MUSD in milestone payments, but perhaps only the first 30 MUSD of those could come next year. The €625M from approvals might only come in the following year and the year after that. Royalties for this Orion-patented Opevesostat will also eventually rise to as much as 22 percent of annual sales. But the tests must first succeed and approvals must be obtained. MSD, as one of the world’s largest drug developers, has good chances for this if anyone does. If Orion manages to stick to its strategy of at least a 50% dividend payout, at least €2.25 can be expected for this year. Considering the future outlook, more dividends could certainly be distributed without jeopardizing the promise of increasing dividends in the coming years. The future looks quite good for Orion, and surely many new things are under development. Let’s see how BlackRock plays its game. Quite a lot of the stock trading seems to be concentrated in the closing auction. It might not be worth selling too cheaply.

Tuukka Hirvonen from Orion was presenting about the company as an investment target at Life Science Night.                Topics: 00:00 Orion today 01:05 Business divisions 03:52 Track record 05:40 Financial objectives 06:45 Investment case – key themes 09:23 Orion’s key clinical development pipeline 14:47 Q&A session

Tomorrow, Orion will participate in Inderes’ company evening, which includes the company’s presentation and a Q&A session. Questions can be submitted during the event via chat or through the forum. Messages sent here by tomorrow morning will still be reached.

Orion was covered in Kauppalehti’s Post-Market program.                   Tärkeimmät talousuutiset | Kauppalehti – 7 Dec 25              Jälkipörssi: Cityconin pääomistaja vitkuttelee – Orion-sijoittajat...    Cityconin pääomistaja venytti pakollisen ostotarjouksen aloituksen ensi vuoden puolelle. Jälkipörssi ruotii tällä kertaa Cityconin lisäksi myös Nokian Panimoa ja Orionia.                             There was nothing particularly noteworthy in the comments; only the milestone payment news was commented on in a neutral tone: “In principle, the news was good, although expected by analysts. Reasons for the negative share price reaction can be sought from the fact that the company raised its revenue and operating profit guidance only by the amount of the milestone payment. Most analysts’ revenue forecasts were at the upper end of the new revenue range or above it before the news. The most probable reason is that investors are just too nervous – perhaps now would be a good time to take something to calm down.” Orion is one of the largest direct equity investments in my portfolio (weight approx. 3%), and will remain so for the foreseeable future.

Here are Antti’s comments regarding that recent release.  Orion announced on Wednesday that it would receive a EUR 180 million milestone payment based on the sales of the prostate cancer drug Nubeqa. The milestone payment is the last lump sum related to Nubeqa and will be recorded in the last quarter of 2025. With the confirmation of the payment, the company updated its outlook for 2025. The payment has already been in our forecasts for Q4, so the news does not put pressure on forecast changes.                   Inderes              Orion: viimeinen Nubeqa-etappimaksu varmistui loppuvuodelle - Inderes    Orion saa eturauhassyöpälääke Nubeqan myyntiin perustuvan 180 MEUR:n etappimaksun.

Orion

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 10 MARCH 2025 at 19.00 EET Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with ...

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES 10 MARCH 2025 at 19.00 EET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp; Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025 In accordance with a decision by the Board of Directors, Orion Corporation has on 10 March 2025 transferred altogether 191,911 Orion Corporation B shares held by the company as a share reward for earning period 2022–2024 and a reward for commitment part to the persons belonging to the Share-based Incentive Plan of Orion Group. The transfer is based on the authorisation by the Annual General Meeting of 23 March 2022. The price per share of the transferred shares is EUR 53.7158, which is the volume weighted average quotation of the Orion Corporation B share on 10 March 2025. Accordingly, the total transaction price of the transferred shares is EUR 10,308,652.89. After the share transfer, the total number of own B shares held by Orion Corporation is 440,944. Orion Corporation has informed about the Share-based Incentive Plan in stock exchange release on 10 February 2022. Orion Corporation <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;"><tbody><tr><td style="width:18.52%;;vertical-align: top ;">Liisa Hurme President and CEO</td><td style="width:3.24%;;vertical-align: top ;">&nbsp;&nbsp;&nbsp; </td><td style="width:18.52%;;vertical-align: top ;">Olli Huotari EVP, Corporate Functions</td><td style="width:9.72%;;vertical-align: top ;">&nbsp;</td></tr></tbody></table> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Contact person: Olli Huotari, EVP, Corporate Functions tel. +358 10 426 3054 Publisher: Orion Corporation Communications Orionintie 1A, FI-02200 Espoo, Finland <a href="https://www.globenewswire.com/Tracker?data=eiPBa5s3hcPouBxVpUTcKkFcmDGFgFWW_X0xAAnxMBldI5-dxcL6lKgh6XD9BFtTmDxlU2zrjlKCHkeFFZcsGM-4x5jyKi2XkOqulx3sbq8=">www.orionpharma.com</a> Orion is a globally operating Finnish pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&amp;D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2024 amounted to EUR 1,542 million and the company had about 3,700 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki. <img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTA1Mjk0OCM0MDIwNzMzMjQjMjAwMTk2Mw==" alt=""> <img src="https://ml-eu.globenewswire.com/media/YzlmNTFhYzUtZDlhYi00Njc4LWIwNmUtMGY4ZDg4MjVmMGY5LTEwMTM1MzYtMjAyNS0wMy0xMC1lbg==/tiny/Orion-Oyj.png" alt="">